FG001 Gains FDA Orphan Drug Designation for High-Grade Glioma

Top-line results from a phase 2b trial evaluating FG001 for patients with high-grade glioma are expected by the end of November.

Related Keywords

Denmark ,Copenhagen ,Køavn ,Morten Albrechtsen , ,Accessed October ,News ,Fda ,Brain Cancer ,Articles ,Glioma ,Fg001 ,Fluorophore ,Head And Neck Cancer ,Optical Imaging Agent ,High Grade Glioma ,Fg001 Ct 001 ,2020 003089 38 ,E Ala ,